Serum pyruvate and lactate predict immunotherapy efficacy in advanced gastric cancer: a prospective biomarker study
Frontiers in Immunology · 2025
DOI: 10.3389/fimmu.2025.1663362 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Frontiers in Immunology, 2025. Verfasst von Chang Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huai'an, China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Biomarkers, Tumor, Pyruvic Acid, Lactic Acid. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
While immunotherapy has redefined clinical paradigms for advanced gastric cancer, reliable efficacy prediction remains a critical unmet challenge. Unlike invasive tissue-based predictors, circulating biomarkers offer non-invasive monitoring potential. This study investigated serum energy metabolites, whose dysregulation drove immune evasion, as predictors of therapeutic efficacy in advanced gastric cancer receiving first-line chemoimmunotherapy.
Methods
We conducted a prospective observational study involving 52 patients with advanced gastric cancer receiving first-line chemoimmunotherapy. Serum metabolites of glycolysis and tricarboxylic acid (TCA) cycle were quantified via high-performance liquid chromatography-tandem mass spectrometry. Therapeutic response, progression-free survival (PFS), and overall survival (OS) were served as evaluation endpoints.
Results
Patients exhibiting decreased serum concentrations of glycolytic metabolites (lactate and pyruvate) demonstrated significantly higher disease control rate (DCR) compared to those with elevated concentrations. Elevated serum lactate and pyruvate were significantly associated with inferior PFS and OS. Multivariate Cox regression established low lactate and pyruvate as independent prognostic factors for improved PFS and OS. However, no significant associations were observed between serum TCA cycle metabolites (citrate, isocitrate, α-ketoglutarate, succinate, fumarate, malate, and oxaloacetate) and DCR, PFS, or OS.
Conclusion
Our findings suggest that serum lactate and pyruvate as non-invasive glycolytic biomarkers with substantial predictive value for immunotherapy efficacy in advanced gastric cancer, requiring validation in larger cohorts to guide therapeutic decisions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huai'an, China.
- Department of stomatology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huai'an, China.
- Department of Hematology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huai'an, China.
- Northern Jiangsu Institute of Clinical Medicine, Nanjing Medical University, Huai'an, China.
- Department of Oncology, The Huaian Clinical College of Xuzhou Medical University, Huai'an, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Liu, C., Dai, Y., Wang, J., Wu, J., & Wei, B. (2025). Serum pyruvate and lactate predict immunotherapy efficacy in advanced gastric cancer: a prospective biomarker study. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2025.1663362
Vancouver
Liu C, Dai Y, Wang J, Wu J, Wei B. Serum pyruvate and lactate predict immunotherapy efficacy in advanced gastric cancer: a prospective biomarker study. Frontiers in Immunology. 2025. doi:10.3389/fimmu.2025.1663362
BibTeX
@article{Liu2025,
author = {Liu, Chang and Dai, Ying and Wang, Jiru and Wu, Jingjing and Wei, Bin},
title = {Serum pyruvate and lactate predict immunotherapy efficacy in advanced gastric cancer: a prospective biomarker study},
journal = {Frontiers in Immunology},
year = {2025},
doi = {10.3389/fimmu.2025.1663362}
}
EUVIMED